ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01981837
Recruitment Status : Completed
First Posted : November 13, 2013
Last Update Posted : January 29, 2018
Sponsor:
Information provided by (Responsible Party):
Alnylam Pharmaceuticals

Brief Summary:
The purpose of this study is to determine the pharmacokinetics, pharmacodynamics and exploratory clinical activity of ALN-TTRSC (revusiran) in Patients with Transthyretin (TTR) Cardiac Amyloidosis.

Condition or disease Intervention/treatment Phase
TTR-mediated Amyloidosis Drug: ALN-TTRSC (revusiran) for subcutaneous administration Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 26 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2, Open-Label Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Exploratory Clinical Activity of ALN-TTRSC in Patients With Transthyretin (TTR) Cardiac Amyloidosis
Study Start Date : December 2013
Actual Primary Completion Date : October 2014
Actual Study Completion Date : January 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Amyloidosis
U.S. FDA Resources

Arm Intervention/treatment
Experimental: ALN-TTRSC (revusiran) Drug: ALN-TTRSC (revusiran) for subcutaneous administration



Primary Outcome Measures :
  1. The proportion of subjects experiencing adverse events (AEs), serious adverse events (SAEs) and study drug discontinuation. [ Time Frame: Up to 63 days ]

Secondary Outcome Measures :
  1. Pharmacokinetics (PK) of ALN-TTRSC (revusiran) (Cmax, tmax, t1/2, AUC, CL, Vss, Vz) [ Time Frame: Up to 90 days ]
  2. Effect of ALN-TTRSC (revusiran) on transthyretin (TTR) (Determination of % Lowering of TTR to pretreatment/Baseline Levels) [ Time Frame: Up to 90 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • TTR cardiac amyloidosis;
  • Women of child-bearing potential (WOCBP) must have a negative pregnancy test, cannot be breast feeding, and must be willing to use 2 highly effective methods of contraception;
  • Male subjects agree to use appropriate contraception;
  • Adequate blood counts, liver, renal and heart function;
  • Adequate Karnofsky performance status;
  • Adequate New York Heart Association (NYHA) Classification Score;
  • Clinically stable on heart medications;
  • Adequate 6-minute walk test;
  • Willing to give written informed consent and are willing to comply with the study requirements.

Exclusion Criteria:

  • Known human immunodeficiency virus (HIV) positive status or known or suspected systemic bacterial, viral, parasitic, or fungal infection;
  • Subjects with a history of multiple drug allergies or intolerance to SC injection;
  • Received an investigational agent other than tafamidis, diflunisal, doxycycline or tauroursodeoxycholic acid, or an investigational device within 30 days prior to first dose of study;
  • Uncontrolled hypertension, ischemic heart disease or cardiac arrhythmia;
  • Untreated hypo- or hyperthyroidism;
  • Prior major organ transplant;
  • Considered unfit for the study by the Principal Investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01981837


Locations
United States, Massachusetts
Clinical Trial Site
Boston, Massachusetts, United States, 02155
United States, New York
Clinical Trial Site
New York, New York, United States, 10034
United States, Ohio
Clinical Trial Site
Cleveland, Ohio, United States, 44195
United Kingdom
Clinical Trial Site
London, United Kingdom, UK NW3 2PF
Sponsors and Collaborators
Alnylam Pharmaceuticals
Investigators
Study Director: Jared Gollob, MD Alnylam Pharmaceuticals

Responsible Party: Alnylam Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01981837     History of Changes
Other Study ID Numbers: ALN-TTRSC-002
First Posted: November 13, 2013    Key Record Dates
Last Update Posted: January 29, 2018
Last Verified: January 2018

Keywords provided by Alnylam Pharmaceuticals:
RNAi therapeutic

Additional relevant MeSH terms:
Amyloidosis
Proteostasis Deficiencies
Metabolic Diseases